Phase 2 N=6 Inhibition of Anaphylaxis by Ibrutinib
Food Allergy · Anaphylaxis Food
Primary: Number of Doses of Ibrutinib for Maximal Suppression of Skin Prick Test Size to Foods — 2 doses — p=<0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=20 Fluciclovine and PSMA PET/CT for the Classification and Improved Staging of Invasive Lobular Breast Cancer
Anatomic Stage IV Breast Cancer AJCC v8 · Invasive Breast Lobular Carcinoma · Metastatic Breast Lobular Carcinoma
Primary: Verified Detection Rate for Metastasis — 5.9; 5.5 SUVMax
Phase 2 N=192 Safety and Immunogenicity of the Dengue Virus Vaccine TV005 (TetraVax-DV TV005) in Healthy Adults, Adolescents, and Children in Dhaka, Bangladesh
Dengue
Primary: Percentage of Study Participants With Each Solicited, Related Adverse Event Types of Any Severity. — 1; 0; 1; 0 Participants
Phase 1 N=25 A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors
Minimal Residual Disease · KRAS G12D · KRAS G12R
Primary: The Participant Incidence of Treatment-emergent Adverse Events Considered by the Investigator as Related to ELI-002 — 1; 3; 2; 2 Participants
Phase 4 N=6 A Study Evaluating the Efficacy and Tolerability of Enstilar Foam in Patients With Nail Psoriasis
Nail Psoriasis
Primary: Clinical Improvement in Nail Thickness of Target Nail at Week 24 Compared to Baseline. — 2 Participants who experienced improvement
Phase 4 N=66 High-dose vs. Standard-dose Cephalexin for Cellulitis
Cellulitis
Primary: Patient Recruitment Rate — 51.5 percentage of eligible patients
N/A N=72 Comparison of Total Oxidant and Total Antioxidant Capacities in Low-Flow and High-Flow General Anesthesia
Oxidative Stress · Anesthesia
Primary: Comparison of Total Antioxidant Status (TAS) Levels Between the Two Groups — 1.76; 1.82; 1.83; 1.92 mmol Eq / L
Phase 2 N=195 Phase II Randomized Trial of Bethesda Protocol Compared to Cambridge Method for Detection of Early Stage Gastric Cancer in CDH1 Mutation Carriers
Gastric Cancer · Gastric Neoplasms · Gastric Adenocarcinoma
Primary: Proportion of Participants With Improved Sensitivity for Detection of Early-stage Gastric Cancer in CDH1 Germline Mutation Carriers Compared to the Cambridge Method — 1…
N/A N=143 Evaluation of Four Injectable Neuromodulators in the Glabella Area Glabella Area
Cosmetic Techniques
Primary: the Change in Dynamic Strain in the Glabella Area After Injection Over Time — 6.4; 10.9; 6.6; 8.9 percent difference of neutral+dyanamic
N/A N=120 Performance of Contour Next® and Contour Plus Elite® BGMS in Arterial Blood Samples From Hospitalized Adults
Diabetes Mellitus
Primary: Number of Results From the Contour Next BGMSs Reference Values Within ±12.5% of Reference Values — 236 blood samples
N/A N=179 Motivational Interviewing and Guided Opioid Tapering Support to Promote Postoperative Opioid Cessation
Opioid Cessation
Primary: Time to Opioid Cessation — 28; 25 days
Phase 2 N=12 Study Evaluating the Safety and Efficacy of PTX-022 (QTORIN Sirolimus) in the Treatment of Microcystic Lymphatic Malformations
Microcystic Lymphatic Malformation
Primary: Incidence of Treatment-Emergent Adverse Events — 9; 2; 6; 2 participants
N/A N=60 Conduction System Pacing Optimized Therapy
Heart Failure
Primary: Electrical Synchronization Response — 15.18; 17.04 Difference in percent change in SDAT
Phase 1 N=37 Safety Study of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts in Adolescents
Allergic Rhinitis Due to House Dust Mite
Primary: Safety and Tolerability Evaluated on Treatment Emergent Adverse Events — 4; 6; 9; 4 participants
Phase 3 N=683 A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Glycosylated Haemoglobin (HbA1c) — -1.40; -0.86 Percentage point of HbA1c — p=<0.0001